Morgan Stanley Precision Biosciences Inc Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.29 - $0.45 $96,903 - $150,367	334,149 New	334,149 $120,000
Q4 2023 Feb 13, 2024	BUY	$0.29 - $0.45 $30,230 - $46,909	104,243 Added 45.34%	334,149 $120,000
Q3 2023 Nov 15, 2023	SELL	$0.34 - $0.69 $8,500 - $17,250	-25,000 Reduced 9.81%	229,906 $78,000
Q2 2023 Aug 14, 2023	BUY	$0.52 - $0.91 $17,077 - $29,886	32,842 Added 14.79%	254,906 $135,000
Q1 2023 May 15, 2023	SELL	$0.7 - $1.41 $63,397 - $127,700	-90,568 Reduced 28.97%	222,064 $166,000
Q4 2022 Feb 14, 2023	SELL	$0.97 - $45.0 $249,366 - $11.6 Million	-257,079 Reduced 45.12%	312,632 $372,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $40.8 $486,232 - $16.3 Million	-398,551 Reduced 41.16%	569,711 $740,000
Q2 2022 Oct 27, 2022	BUY	$1.15 - $3.34 $698,734 - $2.03 Million	607,595 Added 168.46%	968,262 $1.55 Million
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.34 $698,734 - $2.03 Million	607,595 Added 168.46%	968,262 $1.55 Million
Q1 2022 Oct 27, 2022	SELL	$2.96 - $7.76 $1.8 Million - $4.71 Million	-607,595 Reduced 62.75%	360,667 $1.11 Million
Q1 2022 May 13, 2022	BUY	$2.96 - $7.76 $469,766 - $1.23 Million	158,705 Added 78.58%	360,667 $1.11 Million
Q4 2021 Feb 14, 2022	SELL	$7.4 - $11.66 $1.29 Million - $2.03 Million	-174,034 Reduced 46.29%	201,962 $1.5 Million
Q3 2021 Nov 15, 2021	BUY	$9.18 - $14.15 $3.45 Million - $5.32 Million	375,996 New	375,996 $4.34 Million

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $561M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.